CINECA IRIS Institutional Research Information System

CAVALLO, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.564
EU - Europa 4.067
AS - Asia 2.597
SA - Sud America 160
OC - Oceania 121
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 5
Totale 12.560
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.345
CN - Cina 1.424
IT - Italia 967
IE - Irlanda 450
SE - Svezia 368
FR - Francia 348
GB - Regno Unito 328
DE - Germania 325
JP - Giappone 295
IN - India 186
FI - Finlandia 182
AT - Austria 177
UA - Ucraina 168
CA - Canada 164
KR - Corea 154
ES - Italia 135
PL - Polonia 135
AU - Australia 107
VN - Vietnam 98
TR - Turchia 76
CH - Svizzera 75
NL - Olanda 72
GR - Grecia 70
BR - Brasile 65
HK - Hong Kong 63
RU - Federazione Russa 59
SG - Singapore 52
TH - Thailandia 47
BE - Belgio 46
MX - Messico 44
TW - Taiwan 41
PT - Portogallo 31
IL - Israele 27
NO - Norvegia 24
SN - Senegal 23
CL - Cile 22
AR - Argentina 21
DK - Danimarca 19
MY - Malesia 19
SA - Arabia Saudita 19
HU - Ungheria 18
PE - Perù 18
CO - Colombia 17
PH - Filippine 15
IR - Iran 14
NZ - Nuova Zelanda 14
PK - Pakistan 14
UZ - Uzbekistan 13
RO - Romania 12
BY - Bielorussia 10
CZ - Repubblica Ceca 8
EC - Ecuador 6
HR - Croazia 6
SK - Slovacchia (Repubblica Slovacca) 6
BG - Bulgaria 5
BO - Bolivia 5
EE - Estonia 5
EU - Europa 5
ID - Indonesia 5
OM - Oman 5
AE - Emirati Arabi Uniti 4
CU - Cuba 4
EG - Egitto 4
JO - Giordania 4
MK - Macedonia 4
SI - Slovenia 4
VE - Venezuela 4
ZA - Sudafrica 4
MA - Marocco 3
NG - Nigeria 3
PS - Palestinian Territory 3
AL - Albania 2
AM - Armenia 2
BD - Bangladesh 2
BH - Bahrain 2
DZ - Algeria 2
GE - Georgia 2
KW - Kuwait 2
KZ - Kazakistan 2
MT - Malta 2
PR - Porto Rico 2
RS - Serbia 2
SC - Seychelles 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UY - Uruguay 2
BS - Bahamas 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
IM - Isola di Man 1
IQ - Iraq 1
KE - Kenya 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
Totale 12.558
Salva come PNG Salva come JPEG
Città #
Beijing 568
Chandler 555
Dublin 443
Ashburn 298
Fairfield 278
Houston 254
Redwood City 196
Torino 170
Vienna 166
Jacksonville 165
Ann Arbor 154
Shanghai 146
Wilmington 140
Seattle 133
Woodbridge 133
Nyköping 130
Princeton 130
Villeurbanne 120
Dearborn 119
Medford 112
Cambridge 98
Warsaw 82
San Mateo 76
Duncan 70
Milan 70
Rome 69
Pisa 61
Boston 59
New York 56
Tokyo 56
Fremont 55
Turin 54
Guangzhou 51
Nanjing 51
Dong Ket 47
London 46
Chengdu 44
Washington 42
Sydney 40
Boardman 39
Hangzhou 38
Toronto 36
Florence 35
Athens 33
Chennai 32
Zhengzhou 31
Norwalk 30
Bologna 29
Hebei 29
Rochester 29
Ankara 27
Ottawa 25
Paris 25
Atlanta 24
Barcelona 24
Madrid 24
Philadelphia 24
San Diego 24
Taipei 24
Chicago 23
Central 21
Jinan 19
Singapore 19
Collegeville 18
Lima 18
Bengaluru 17
Berlin 17
Guiyang 17
Oslo 17
São Paulo 17
Bangkok 16
Hefei 16
Melbourne 16
Munich 16
Zurich 16
Brussels 15
Fuzhou 15
Hyderabad 15
Los Angeles 15
Polska 15
Seoul 15
Wuhan 15
Brisbane 14
Manchester 14
Montreal 14
New Delhi 14
San Francisco 14
Tianjin 14
Xian 14
Changsha 13
Istanbul 13
Mumbai 13
Budapest 12
Des Moines 12
Newburyport 12
Buenos Aires 11
Central District 11
Chongqing 11
Frankfurt am Main 11
Jerusalem 11
Totale 6.735
Salva come PNG Salva come JPEG
Nome #
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial 1.666
ABVD vs BEACOPP escalated in advanced-stage Hodgkin’s lymphoma: Results from a multicenter European study 1.008
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 897
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma 518
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma 461
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma 420
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 338
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma 318
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents 291
Role of consolidation/maintenance therapy in multiple myeloma. 222
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. 205
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 203
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 186
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide 178
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials 145
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. 139
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies 138
AISF position paper on HCV in immunocompromised patients 118
Psychological distress and oral chemotherapy: a pilot study. 112
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL) 111
Integration of COO into the clinical CNS International Prognostic Index could improve CNS relapse prediction in DLBCL 106
High-risk myeloma: when to transplant-or not. 105
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome 105
12p, 1p, 1q, 5q, 11q ABNORMALITIES AND IMMUNOPHENOTYPE IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA. 98
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL 97
Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy. 94
CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE IN MULTIPLE MYELOMA 94
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 94
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone 92
Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma 90
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 89
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients. 87
Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide 84
A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients 83
A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS. 83
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS 81
Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives. 81
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients 80
THROMBOPROPHYLAXIS FOR NEWLY DIAGNOSED MULTIPLEMYELOMA PATIENTS TREATED WITH LENALIDOMIDE-BASEDREGIMENS: A RANDOMIZED PHASE III STUDY OF ASPIRINVS ENOXAPARIN 80
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 80
A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis. 80
Oral chemotherapy: an innovative choice 79
Droplet Digital PCR Assay for MYD88L265P 77
Real life use of bendamustine in elderly patients with lymphoid neoplasia 77
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 76
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 75
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 73
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 73
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome 70
The treatment of the elderly multiple myeloma patients 67
MULTIPLE MYELOMA: CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE 67
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma 65
Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol 65
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma 64
Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3) 63
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR 62
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 62
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 60
CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE IN MULTIPLE MYELOMA 59
Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study 58
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation 56
Clinical and biological features of multiple myeloma involving the gastrointestinal system 55
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients 55
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial 55
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 55
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant 53
COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment 51
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 50
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. 49
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma 49
Hyperammonemia and encephalopathy in patients with multiple myeloma 48
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. 48
Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma 47
Piedmont and Aosta Valley Consortium of Systemic Amyloidosis: results of a four year experience 47
Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases 47
Review of thalidomide in the treatment of newly diagnosed multiple myeloma 46
Oral melphalan, prednisone,and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 46
Response to bortezomib and activation of osteoblasts in multiple myeloma 46
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 45
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant 45
Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma 44
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 44
Lenalidomide and its role in the management of multiple myeloma 43
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. 43
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 42
The hemostatic system and malignancy 40
Defibrotide: a review on clinical use and future development. 40
MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSO MELPHALAN (200 MG/M2) E TRAPIANTO AUTOLOGO (MEL200) IN PAZIENTI CON NUOVA DIAGNOSI DI MIELOMA MULTIPLO (MM): UNO STUDIO DI FASE III. 40
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma 40
INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA 39
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. 37
INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) DETEDTION OF CHROMOSOME 13 ABNORMALITIES (DEL 13) IN MULTIPLE MYELOMA 37
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 36
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy 35
Stem cell mobilization in newly diagnosed multiple myeloma patients after lenalidomide 35
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 35
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma 34
Phase I study of the anti insulin-like growth factor1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and incombination with bortezomib in patients with relapsed multiple myeloma. 34
Farnesyltransferase inhibitors and rapamycinin the treatment of multiple myeloma 33
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)) 33
Totale 12.606
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.158
article - articoli 0
book - libri 0
conference - conferenze 6.292
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.450
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019319 0 0 0 0 0 0 0 0 0 60 179 80
2019/20201.152 58 51 45 146 74 186 153 94 109 88 88 60
2020/20211.908 121 58 158 145 173 122 146 129 192 193 207 264
2021/20222.700 154 163 195 244 201 195 282 229 156 210 336 335
2022/20232.894 237 209 101 250 260 549 245 204 282 196 177 184
2023/20241.880 207 264 166 168 263 274 194 173 42 129 0 0
Totale 13.018